Next Generation Mpro Inhibitor (Pardes Biosciences)

N/A

Report date: 2025/01/26 15:51:03
NME

Base Information

Drug NameNext Generation Mpro Inhibitor (Pardes Biosciences)
Drug Alias Name3CL protease inhibitor (Pardes Biosciences)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors
TargetsSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPardes Biosciences Sub Inc
China Registration ClassN/A

Develop Information

Active CompaniesPardes Biosciences Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A